Potent in vivo antinociception and opioid receptor preference of the novel analogue [Dmt1]endomorphin-1

Pharmacology Biochemistry and Behavior

Volumn 84, Issue 2, 2006, Pages 252-258

  Jinsmaa, Yunden ^a   Marczak, Ewa ^a   Fujita, Yoshio ^b   Shiotani, Kimitaka ^b   Miyazaki, Anna ^b   Li, Tingyou ^b   Tsuda, Yuko ^b   Ambo, Akihiro ^c   Sasaki, Yusuke ^c   Bryant, Sharon D ^a   Okada, Yoshio ^b   Lazarus, Lawrence H ^a  

^a NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

^b KOBE GAKUIN UNIVERSITY   (Japan)

^c TOHOKU PHARMACEUTICAL UNIVERSITY   (Japan)

Author keywords

Antinociception; Dimethyltyrosine; Endomorphin; Opioid receptor subtypes; Spinal; Supraspinal

Indexed keywords

BETA FUNALTREXAMINE; DELTA OPIATE RECEPTOR; ENDOMORPHIN 1; ENDORPHIN DERIVATIVE; MU OPIATE RECEPTOR AGONIST; MU OPIATE RECEPTOR ANTAGONIST; NALOXONAZINE; NALOXONE; NALTRINDOLE; NATURAL RESISTANCE ASSOCIATED MACROPHAGE PROTEIN 2; OPIATE ANTAGONIST; OPIATE RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTINOCICEPTION; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG ANTAGONISM; DRUG POTENCY; GUINEA PIG; HOT PLATE TEST; IN VIVO STUDY; MALE; MOUSE; MOUSE STRAIN; NOCICEPTION; NONHUMAN; PAIN; PRIORITY JOURNAL; SPINE; STATISTICAL SIGNIFICANCE; TAIL FLICK TEST;

ANALGESIA; ANIMALS; BRAIN; GUINEA PIGS; ILEUM; INJECTIONS, INTRAVENTRICULAR; MALE; MICE; NALOXONE; NALTREXONE; OLIGOPEPTIDES; PAIN; PAIN MEASUREMENT; RECEPTORS, OPIOID, DELTA; RECEPTORS, OPIOID, MU; SPINAL CORD; TAIL; VAS DEFERENS;

EID: 33746305665     PISSN: 00913057     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pbb.2006.05.005     Document Type: Article

References (32)

1. Banks W.A., and Kastin A.J. Passage of peptides across the blood-brain barrier: pathophysiological perspectives. Life Sci 59 (1996) 1923-1943
2. Bryant S.D., Jinsmaa Y., Salvadori S., Okada Y., and Lazarus L.H. Dmt and opioid peptides: a potent alliance. Biopolymers 71 (2003) 86-102
3. Cheng Y., and Prusoff W.H. Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochem Pharmacol 22 (1973) 3099-3108
4. Craft R.M., Henley S.R., Haaseth R.C., Hruby V.J., and Porreca F. Opioid antinociception in a rat model of visceral pain: systemic versus local drug administration. J Pharmacol Exp Ther 275 (1995) 1535-1542
5. DeHaven-Hudkins D.L., and Dolle R.E. Peripherally restricted opioid agonists as novel analgesic agents. Curr Pharm Des 10 (2004) 743-757
6. Dygos J.H., Yonan E.E., Scaros M.G., Goodmonson O.J., Getman D.P., Periana R.A., et al. A convenient asymmetric synthesis of the unnatural amino acid 2,6-dimethyl-L-tyrosine. Synthesis 89 (1992) 741-743
7. Fujita Y., Tsuda Y., Li T., Motoyama T., Takahashi M., Shimizu Y., et al. Development of potent bifunctional endomorphin-2 analogues with mixed mu-/delta-opioid agonist and delta-opioid antagonist properties. J Med Chem 47 (2004) 3591-3599
8. Fujita Y., Tsuda Y., Motoyama T., Li T., Miyazaki A., Yokoi T., et al. Studies on the structure-activity relationship of 2′,6′-dimethyl-l-tyrosine (Dmt) derivatives: bioactivity profile of H-Dmt-NH-CH(3). Bioorg Med Chem Lett 15 (2005) 599-602
9. Goldberg I.E., Rossi G.C., Letchworth S.R., Mathis J.P., Ryan-Moro J., Leventhal L., et al. Pharmacological characterization of endomorphin-1 and endomorphin-2 in mouse brain. J Pharmacol Exp Ther 286 (1998) 1007-1013
10. Heyman J.S., Williams C.L., Burks T.F., Mosberg H.I., and Porreca F. Dissociation of opioid antinociception and central gastrointestinal propulsion in the mouse: studies with naloxonazine. J Pharmacol Exp Ther 245 (1988) 238-243
11. Horvath G. Endomorphin-1 and endomorphin-2: pharmacology of the selective endogenous mu-opioid receptor agonists. Pharmacol Ther 88 (2000) 437-463
12. Jinsmaa Y., Okada Y., Tsuda Y., Shiotani K., Sasaki Y., Ambo A., et al. Novel 2′,6′-dimethyl-L-tyrosine-containing pyrazinone opioid mimetic mu-agonists with potent antinociceptive activity in mice. J Pharmacol Exp Ther 309 (2004) 432-438
13. Jinsmaa Y., Fujita Y., Shiotani K., Miyazaki A., Li T., Tsuda Y., et al. Differentiation of opioid receptor preference by [Dmt1]endomorphin-2-mediated antinociception in the mouse. Eur J Pharmacol 509 (2005) 37-42
14. Laursen S.E., and Belknap J.K. Intracerebroventricular injections in mice. Some methodological refinements. J Pharmacol Methods 16 (1986) 355-357
15. Li T., Fujita Y., Tsuda Y., Miyazaki A., Ambo A., Sasaki Y., et al. Development of potent mu-opioid receptor ligands using unique tyrosine analogues of endomorphin-2. J Med Chem 48 (2005) 586-592
16. Ling G.S., and Pasternak G.W. Spinal and supraspinal opioid analgesia in the mouse: the role of subpopulations of opioid binding sites. Brain Res 271 (1983) 152-156
17. Narita M., Mizoguchi H., Oji G.S., Tseng E.L., Suganuma C., Nagase H., et al. Characterization of endomorphin-1 and -2 on [35S]GTPgammaS binding in the mouse spinal cord. Eur J Pharmacol 351 (1998) 383-387
18. Okada Y., Fujita Y., Motoyama T., Tsuda Y., Yokoi T., Li T., et al. Structural studies of [2′,6′-dimethyl-L-tyrosine1]endomorphin-2 analogues: enhanced activity and cis orientation of the Dmt-Pro amide bond. Bioorg Med Chem 11 (2003) 1983-1994
19. Okada Y., Tsuda Y., Fujita Y., Yokoi T., Sasaki Y., Ambo A., et al. Unique high-affinity synthetic mu-opioid receptor agonists with central- and systemic-mediated analgesia. J Med Chem 46 (2003) 3201-3209
20. Paul D., Bodnar R.J., Gistrak M.A., and Pasternak G.W. Different mu receptor subtypes mediate spinal and supraspinal analgesia in mice. Eur J Pharmacol 168 (1989) 307-314
21. Porreca F., Cowan A., and Tallarida R.J. Time course of antagonism of morphine antinociception by intracerebroventricularly administered naloxone in the rat. Eur J Pharmacol 76 (1981) 55-59
22. Portoghese P.S., Sultana M., and Takemori A.E. Naltrindole, a highly selective and potent non-peptide delta opioid receptor antagonist. Eur J Pharmacol 146 (1988) 185-186
23. Sakurada S., Zadina J.E., Kastin A.J., Katsuyama S., Fujimura T., Murayama K., et al. Differential involvement of mu-opioid receptor subtypes in endomorphin-1- and -2-induced antinociception. Eur J Pharmacol 372 (1999) 25-30
24. Sakurada C., Sakurada S., Hayashi T., Katsuyama S., Tan-No K., and Sakurada T. Degradation of endomorphin-2 at the supraspinal level in mice is initiated by dipeptidyl peptidase IV: an in vitro and in vivo study. Biochem Pharmacol 66 (2003) 653-661
25. Salvadori S., Balboni G., Guerrini R., Tomatis R., Bianchi C., Bryant S.D., et al. Evolution of the Dmt-Tic pharmacophore: N-terminal methylated derivatives with extraordinary delta opioid antagonist activity. J Med Chem 40 (1997) 3100-3108
26. Shane R., Wilk S., and Bodnar R.J. Modulation of endomorphin-2-induced analgesia by dipeptidyl peptidase IV. Brain Res 815 (1999) 278-286
27. Spampinato S., Qasem A.R., Calienni M., Murari G., Gentilucci L., Tolomelli A., et al. Antinociception by a peripherally administered novel endomorphin-1 analogue containing beta-proline. Eur J Pharmacol 469 (2003) 89-95
28. Stone L.S., Fairbanks C.A., Laughlin T.M., Nguyen H.O., Bushy T.M., Wessendorf M.W., et al. Spinal analgesic actions of the new endogenous opioid peptides endomorphin-1 and-2. Neuroreport 8 (1997) 3131-3135
29. Tseng L.F., Narita M., Suganuma C., Mizoguchi H., Ohsawa M., Nagase H., et al. Differential antinociceptive effects of endomorphin-1 and endomorphin-2 in the mouse. J Pharmacol Exp Ther 292 (2000) 576-583
30. Tung A.S., and Yaksh T.L. In vivo evidence for multiple opiate receptors mediating analgesia in the rat spinal cord. Brain Res 247 (1982) 75-83
31. Yeung J.C., and Rudy T.A. Sites of antinociceptive action of systemically injected morphine: involvement of supraspinal loci as revealed by intracerebroventricular injection of naloxone. J Pharmacol Exp Ther 215 (1980) 626-632
32. Zadina J.E., Hackler L., Ge L.J., and Kastin A.J. A potent and selective endogenous agonist for the mu-opiate receptor. Nature 386 (1997) 499-502